Table 3.
Ligands | Frequency | |
---|---|---|
Patients (n=50) | Controls (n=54) | |
HLA-CAsn80 | 18 (36.0%) | 16 (29.63%) |
HLA-CLys80 | 6 (12.0%)* | 17 (31.48%) |
HLA-CLys80;Asn80 | 26 (52.0%) | 21 (38.89%) |
*p=0.017; OR=0.270; 95% CI, 0.09–0.91
Ligands | Frequency | |
---|---|---|
Patients (n=50) | Controls (n=54) | |
HLA-CAsn80 | 18 (36.0%) | 16 (29.63%) |
HLA-CLys80 | 6 (12.0%)* | 17 (31.48%) |
HLA-CLys80;Asn80 | 26 (52.0%) | 21 (38.89%) |
*p=0.017; OR=0.270; 95% CI, 0.09–0.91